Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Net Income towards Common Stockholders: 2014-2025

Historic Net Income towards Common Stockholders for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to -$67.3 million.

  • ImmunityBio's Net Income towards Common Stockholders rose 21.55% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 40.68%. This contributed to the annual value of -$413.6 million for FY2024, which is 29.15% up from last year.
  • As of Q3 2025, ImmunityBio's Net Income towards Common Stockholders stood at -$67.3 million, which was up 27.35% from -$92.6 million recorded in Q2 2025.
  • ImmunityBio's 5-year Net Income towards Common Stockholders high stood at -$59.2 million for Q4 2024, and its period low was -$233.4 million during Q4 2023.
  • In the last 3 years, ImmunityBio's Net Income towards Common Stockholders had a median value of -$116.6 million in 2023 and averaged -$117.0 million.
  • In the last 5 years, ImmunityBio's Net Income towards Common Stockholders tumbled by 115.47% in 2023 and then spiked by 74.65% in 2024.
  • ImmunityBio's Net Income towards Common Stockholders (Quarterly) stood at -$91.6 million in 2021, then declined by 18.32% to -$108.3 million in 2022, then crashed by 115.47% to -$233.4 million in 2023, then surged by 74.65% to -$59.2 million in 2024, then increased by 21.55% to -$67.3 million in 2025.
  • Its Net Income towards Common Stockholders was -$67.3 million in Q3 2025, compared to -$92.6 million in Q2 2025 and -$129.7 million in Q1 2025.